A bipartisan group of senators has introduced a bill aimed at lowering the cost of insulin for millions of Americans. The legislation would cap the monthly cost of the life-saving drug at $35 for individuals with private insurance plans.

The INSULIN Act: Key Provisions

The bill, introduced last week by Senators Jeanne Shaheen (D-Maine), Raphael Warnock (D-Ga.), Susan Collins (R-Maine), and John Kennedy (R-La.), also includes a pilot program to increase access to affordable insulin for uninsured Americans in ten states. This program aims to address a critical gap in coverage for those who struggle to afford the medication.

Building on Previous Efforts

A similar measure was included in the 2022 Inflation Reduction Act, successfully lowering out-of-pocket insulin costs for Medicare beneficiaries. However, this new bill seeks to extend those savings to a broader population with private insurance.

Challenges and Hurdles

Despite the bipartisan support, the bill faces potential obstacles, including concerns about cost and competing priorities in Congress. Previous attempts to pass similar legislation have stalled, highlighting the challenges of navigating the legislative process.

The Scope of the Problem

Approximately 8.1 million people in the U.S. use insulin, according to the Centers for Disease Control and Prevention. Over 2 million of these individuals have Type 1 diabetes and require regular insulin access to survive. The drug is also crucial for managing glucose levels in other forms of diabetes.

Uneven Access and Affordability

While some individuals with private insurance pay little to nothing for insulin, costs can vary significantly. Approximately 57% of Americans with private health insurance are covered by self-insured plans that are not subject to state cost-cap regulations, leaving them vulnerable to high prices. Many others are uninsured or face difficulties accessing manufacturer savings programs.

Industry and Advocate Responses

Dr. Leslie Eiland, an endocrinologist at the University of Nebraska Medical Center, emphasized the need to shift the burden of cost reduction from patients. Pharmaceutical companies like Sanofi and Novo Nordisk have highlighted their existing savings programs and commitment to affordability. PhRMA, the pharmaceutical trade association, pointed to pharmacy benefit managers and insurers as contributing to access and affordability barriers.

Personal Impact and Hope for the Future

Breana Glover, a 23-year-old living in Houston, shared her experience of moving to Texas to reduce living expenses and afford her diabetes care. A $35 monthly cap would significantly ease her financial burden. Manny Hernandez, CEO of The Diabetes Link, expressed optimism about recent meetings with Republican lawmakers but acknowledged the potential for competing priorities to derail the bill.